Literature DB >> 20739943

Genetics of Moyamoya disease.

Constantin Roder1, Nikhil R Nayak, Nadia Khan, Marcos Tatagiba, Ituro Inoue, Boris Krischek.   

Abstract

Moyamoya disease (MMD) is a disease pattern consisting of bilateral stenosis of the intracranial internal carotid arteries (ICA) accompanied by a network of abnormal collateral vessels that bypass the stenosis. Once symptomatic, insufficient cerebral blood flow or rupture of the fragile collaterals may cause stroke or hemorrhage, resulting in severe neurological dysfunction or death. The etiology of MMD is still unknown, although few associations with other diseases and environmental factors have been described. Strong regional differences in epidemiological data, as well as known familial cases, turned the focus to genetics for the insight into the disease's pathogenesis. Thus far, several reports have suggested specific genetic loci and individual genes as predisposing to MMD, but none have demonstrated reproducible results in independent cohorts. Small sample sizes, as well as a likely multifactorial origin, seem to be the most challenging tasks in identifying the disease-causing mechanisms. Once identified, susceptibility genes may allow preventive screening and a possible development of novel therapeutic options.

Entities:  

Mesh:

Year:  2010        PMID: 20739943     DOI: 10.1038/jhg.2010.103

Source DB:  PubMed          Journal:  J Hum Genet        ISSN: 1434-5161            Impact factor:   3.172


  12 in total

1.  Loss of α1β1 soluble guanylate cyclase, the major nitric oxide receptor, leads to moyamoya and achalasia.

Authors:  Dominique Hervé; Anne Philippi; Reda Belbouab; Michel Zerah; Stéphane Chabrier; Sophie Collardeau-Frachon; Francoise Bergametti; Aurore Essongue; Eliane Berrou; Valérie Krivosic; Christian Sainte-Rose; Emmanuel Houdart; Frédéric Adam; Kareen Billiemaz; Marilyne Lebret; Sabine Roman; Sandrine Passemard; Gwenola Boulday; Audrey Delaforge; Stéphanie Guey; Xavier Dray; Hugues Chabriat; Peter Brouckaert; Maryjke Bryckaert; Elisabeth Tournier-Lasserve
Journal:  Am J Hum Genet       Date:  2014-02-27       Impact factor: 11.025

Review 2.  Childhood arterial ischemic stroke: a review of etiologies, antithrombotic treatments, prognostic factors, and priorities for future research.

Authors:  Courtney A Lyle; Timothy J Bernard; Neil A Goldenberg
Journal:  Semin Thromb Hemost       Date:  2011-12-20       Impact factor: 4.180

Review 3.  Recent advances in moyamoya disease: pathophysiology and treatment.

Authors:  Annick Kronenburg; Kees P J Braun; Albert van der Zwan; Catharina J M Klijn
Journal:  Curr Neurol Neurosci Rep       Date:  2014-01       Impact factor: 5.081

4.  Loss of BRCC3 deubiquitinating enzyme leads to abnormal angiogenesis and is associated with syndromic moyamoya.

Authors:  Snaigune Miskinyte; Matthew G Butler; Dominique Hervé; Catherine Sarret; Marc Nicolino; Jacob D Petralia; Francoise Bergametti; Minh Arnould; Van N Pham; Aniket V Gore; Konstantinos Spengos; Steven Gazal; France Woimant; Gary K Steinberg; Brant M Weinstein; Elisabeth Tournier-Lasserve
Journal:  Am J Hum Genet       Date:  2011-05-19       Impact factor: 11.025

5.  Moyamoya angiopathy in a case of Klinefelter syndrome.

Authors:  Ritwik Ghosh; Shambaditya Das; Dipayan Roy; Adrija Ray; Julián Benito-León
Journal:  Childs Nerv Syst       Date:  2021-10-10       Impact factor: 1.532

Review 6.  Genetic and Proteomic Contributions to the Pathophysiology of Moyamoya Angiopathy and Related Vascular Diseases.

Authors:  Kirsten B Dorschel; John E Wanebo
Journal:  Appl Clin Genet       Date:  2021-03-18

Review 7.  Moyamoya disease and syndromes: from genetics to clinical management.

Authors:  Stéphanie Guey; Elisabeth Tournier-Lasserve; Dominique Hervé; Manoelle Kossorotoff
Journal:  Appl Clin Genet       Date:  2015-02-16

8.  Molecular analysis of RNF213 gene for moyamoya disease in the Chinese Han population.

Authors:  Zhiyuan Wu; Hanqiang Jiang; Lei Zhang; Xiao Xu; Xinju Zhang; Zhihua Kang; Donglei Song; Jin Zhang; Ming Guan; Yuxiang Gu
Journal:  PLoS One       Date:  2012-10-23       Impact factor: 3.240

9.  DIAPH1 Variants in Non-East Asian Patients With Sporadic Moyamoya Disease.

Authors:  Adam J Kundishora; Samuel T Peters; Amélie Pinard; Daniel Duran; Shreyas Panchagnula; Tanyeri Barak; Danielle F Miyagishima; Weilai Dong; Hannah Smith; Jack Ocken; Ashley Dunbar; Carol Nelson-Williams; Shozeb Haider; Rebecca L Walker; Boyang Li; Hongyu Zhao; Dean Thumkeo; Arnaud Marlier; Phan Q Duy; Nicholas S Diab; Benjamin C Reeves; Stephanie M Robert; Nanthiya Sujijantarat; Amber N Stratman; Yi-Hsien Chen; Shujuan Zhao; Isabelle Roszko; Qiongshi Lu; Bo Zhang; Shrikant Mane; Christopher Castaldi; Francesc López-Giráldez; James R Knight; Michael J Bamshad; Deborah A Nickerson; Daniel H Geschwind; Shih-Shan Lang Chen; Phillip B Storm; Michael L Diluna; Charles C Matouk; Darren B Orbach; Seth L Alper; Edward R Smith; Richard P Lifton; Murat Gunel; Dianna M Milewicz; Sheng Chih Jin; Kristopher T Kahle
Journal:  JAMA Neurol       Date:  2021-08-01       Impact factor: 29.907

10.  The GC + CC genotype at position -418 in TIMP-2 promoter and the -1575GA/-1306CC genotype in MMP-2 is genetic predisposing factors for prevalence of moyamoya disease.

Authors:  Young Seok Park; Young Joo Jeon; Hyun Seok Kim; In Bo Han; Seung-Hun Oh; Dong-Seok Kim; Nam Keun Kim
Journal:  BMC Neurol       Date:  2014-10-04       Impact factor: 2.474

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.